MTOR and nonpapillary renal cell carcinoma: In the meantime, significant breakthroughs have been made in the past two decades, such as introducing vascular endothelial growth factor tyrosine kinase inhibitors (VEGFR TKIs), mammalian target of rapamycin (mTOR) inhibitors, and particularly immune checkpoint inhibitors (ICIs) to better manage patients with ccRCC.